A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus
The main purpose of this study is to assess the efficacy and safety of LY3361237 in participants with at least moderately active systemic lupus erythematosus (SLE).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have systemic lupus erythematosus at least for the last 24 weeks
Participants must be receiving NSAID, antimalarial, steroids or medications that reduce strength of body's immune response
Participants Must Not:
Participants must not have been taking oral steroids at more than 20 milligrams daily
Participants must not have an active infection at least for the last 30 days
Participants must not have hepatitis B or hepatitis C, human immunodeficiency virus (HIV) infection or tuberculosis (TB)
Participants must not have active fibromyalgia
Participants must not have had a unstable heart disease within the last 24 weeks
Participants must not have serious medical condition that could interfere with the analysis of the study
Participants must not have serious risk for suicide
Participants must not be pregnant or nursing
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo